Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.
Liapis K, Papadopoulos V, Vrachiolias G, Galanopoulos AG, Papoutselis M, Papageorgiou SG, Diamantopoulos PT, Pappa V, Viniou NA, Kourakli A, Τsokanas D, Vassilakopoulos TP, Hatzimichael E, Bouronikou E, Ximeri M, Pontikoglou C, Megalakaki A, Zikos P, Panayiotidis P, Dimou M, Karakatsanis S, Papaioannou M, Vardi A, Kontopidou F, Harchalakis N, Adamopoulos I, Symeonidis A, Kotsianidis I.
Liapis K, et al. Among authors: ximeri m.
Blood Cancer J. 2021 Feb 11;11(2):30. doi: 10.1038/s41408-021-00424-4.
Blood Cancer J. 2021.
PMID: 33574231
Free PMC article.
No abstract available.